New Horizons in Cardio Kidney Disease, is a new one-day virtual educational event that took place live on 30 June 2026, designed to address current challenges in cardio-kidney care through practical, cross-disciplinary education, with a focus on biomarker-guided risk assessment, optimisation of blood pressure and cardio-kidney therapies, and emerging multimodal strategies.
Led by course directors Dr Muthiah Vaduganathan (Brigham and Women's Hospital, Boston, US), Dr Neha Pagidipati (Duke Clinical Research Institute, Durham, US), and Prof Smeeta Sinha (Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK), the programme features expert-led presentations, case-based discussions, and multidisciplinary panel sessions. This interactive, collaborative format reflects real-world care pathways and supports the wider implementation of evidence-based strategies in clinical practice.
Watch the full on-demand series* to stay at the forefront of cardio-kidney disease management and enhance your practice with the latest clinical insights.
*Please note, the live version of New Horizons in Cardio Kidney Disease was accredited. This on-demand version is not.
The symposium 'Clinical Utility of eGFR Slope Across Cardio-Kidney Care and Trial Design' is also available to watch here (This session is not intended for UK based HCPs).
Key Learning Objectives
- Increase confidence interpreting albuminuria and integrating biomarkers into risk models
- Improve confidence interpreting BP phenotypes and organ-injury signals to inform escalation decisions
- Improve understanding of therapy sequencing and combination approaches
- Greater adoption of multidisciplinary care pathways
- Enhance readiness for emerging multimodal strategies
Target Audience
- Cardiologists
- Nephrologists
- Primary Care Physicians
- Diabetes Specialists
- Endocrinologists
More from this programme
Part 1
New Horizons in Cardio Kidney Disease: Welcome and Introduction
Neha Pagidipati (Durham, US) and Smeeta Sinha (Salford, UK) introduce the programme and share the key learning objectives.
| 1 session | |
| Welcome and Introduction | Watch now |
Part 2
Session 1: Defining Persistent Risk in Cardio Kidney Disease
Neha Pagidipati (Durham, US) chairs the first session, where faculty focus on defining persistent risk in cardio-kidney disease and exploring the mechanisms that have the greatest relevance for clinical practice. She is joined by Katherine Tuttle (Seattle, US), Erika Jones (Cape Town, SA) and Shelley Zieroth (Winnipeg, CA) for presentations and panel discussion.
Part 3
Session 2: Biomarkers That Guide Decisions
Smeeta Sinha (Salford, UK) chairs this session which demonstrates how biomarkers can identify high-risk patients earlier and enable more informed treatment decisions. She is joined by Navdeep Tangri (Winnipeg, CA), Neha Pagidipati (Durham, US) and Alta Schutte (Sydney, AU) for presentations and panel discussion.
Part 4
Session 3: Optimising Care, From Guidelines to Practice
Muthiah Vaduganathan (Boston, US) chairs this session, which translates risk identification into risk reduction by exploring therapeutic classes and strategies within the context of guideline-directed care, residual risk, and multimodal protection. He is joined by Biykem Bozkurt (Houston, US), Anjay Rastogi (Los Angeles, US) and Hiddo J L Heerspink (Groningen, NL) for presentations and panel discussion.
Part 5
Session 4: Coordinating Multidisciplinary Cardio Kidney Risk Management
Neha Pagidipati (Durham, US) chairs this session and is joined by Anjay Rastogi (Los Angeles, US), Muthiah Vaduganathan (Boston, US) and Smeeta Sinha (Salford, UK). The session explores how multidisciplinary care can improve outcomes.
Part 6
Session 5: Case-Based Decisions Translation
Muthiah Vaduganathan (Boston, US) chairs the final session, a case-based panel discussion that brings together key themes from the previous sessions. A global multidisciplinary panel featuring Jeff Borenstein (Los Angeles, US), Biykem Bozkurt (Houston, US), Erika Jones (Cape Town, SA), Nicholas Jones (Oxford, UK) and Katherine Tuttle (Seattle, US) share their perspectives.
The panel review a case of a 72-year-old male patient. Beyond the case discussion, the panel explore applying biomarker findings to real-world decision-making, navigating therapy sequencing in patients with residual cardio-kidney risk, and identifying multidisciplinary decision points across cardiology, nephrology, and primary care.
Part 7
New Horizons in Cardio Kidney Disease: Close and Key Takeaways
Muthiah Vaduganathan (Boston, US) brings New Horizons in Cardio Kidney Disease 2026 to a close, sharing key insights and takeaways from the day.
| 1 session | |
| Close and Key Takeaways | Watch now |
Faculty Biographies
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a cardiologist and clinical trialist based in Boston, Massachusetts, US, He practices at Brigham and Women’s Hospital and holds an academic appointment at Harvard Medical School. Dr Vaduganathan is internationally recognised for his work at the intersection of cardiovascular, kidney, and metabolic disease, with a particular focus on translating evidence from large-scale clinical trials into routine clinical practice.
Dr Vaduganathan completed his medical training in the US and pursued advanced postgraduate training in cardiovascular medicine, with a focus on heart failure and preventive cardiology. His academic development has been closely aligned with outcomes research, trial methodology, and translational science, positioning him as a leading investigator in cardio-kidney-metabolic therapeutics.
Dr Vaduganathan is widely recognised for his prolific contributions to cardiovascular research and clinical trial leadership. His work has…
Katherine Tuttle
Executive Director of Research
Dr Katherine R Tuttle, is Professor of Medicine in the Nephrology Division and Kidney Research Institute at the University of Washington, US. Executive Director for Research at Providence Inland Northwest Health, and a Co-Principal Investigator for the ITHS. Her major research interests are in the areas of clinical and translational science and precision medicine for diabetic kidney disease, chronic kidney disease, diabetes, and hypertension. Dr Tuttle has led a major patient registry as well as clinical trials in these fields that have delivered breakthrough therapies to prevent kidney failure and cardiovascular events.
Erika SW Jones
Nephrology and Hypertension Specialist
Dr Erika Jones is Associate Professor in the Division of Nephrology and Hypertension at the University of Cape Town and Groote Schuur Hospital in Cape Town, SA.
Dr Jones interests are particularly in hypertension, having done her PhD in this area. One of the aspects of hypertension that she is studying currently and which is of major concern to nephrologists in Cape Town, is the rising incidence of young hypertensives with end stage renal disease in relation to methamphetamine usage.
Biykem Bozkurt
Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America.
Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair; Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine.
Jeff Borenstein
Internist
Dr Jeff Borenstein is Internal Medicine lead for the CKM program at UCLA Health and a board-certified physician in Internal Medicine and Clinical Informatics practicing at UCLA Health Porter Ranch Primary & Specialty Care.
Dr Borenstein graduated from the Mount Sinai Medical School, completing internal medicine residency and fellowships in general internal medicine and health services research at the Cedars-Sinai Medical Center, and obtained a Master’s degree in Public Health from UCLA. He is board-certified in both Internal Medicine and Medical Informatics and is a Fellow of the American College of Physicians. His primary interests are in team-based, interdisciplinary care, primary and secondary prevention through the application of evidence-based medicine, and quality improvement facilitated by electronic health records.
Nicholas Jones
Dr Nicholas Jones is a General Practitioner (GP), GP Cardiologist, and NIHR Clinical Lecturer in General Practice at the University of Oxford, Oxford, UK. Alongside his clinical work as a GP he conducts research focused on the early detection, prevention, and management of cardiovascular, kidney, and metabolic diseases in primary care. His work includes improving the diagnosis of heart failure, stroke prevention in atrial fibrillation, and developing evidence-based approaches to managing long-term conditions.
Dr Jones completed his medical degree at Newcastle University, followed by postgraduate training in Oxford, where he earned a DPhil in Primary Care. He has received national recognition for his research, including the Society for Academic Primary Care Doctoral Prize. Passionate about medical education, he teaches on national GP training courses, supervises postgraduate researchers, and contributes to improving primary care through research, teaching,…